HK1078593A1 - Antibody against a tumor-specific antigen as target - Google Patents

Antibody against a tumor-specific antigen as target

Info

Publication number
HK1078593A1
HK1078593A1 HK06100346.5A HK06100346A HK1078593A1 HK 1078593 A1 HK1078593 A1 HK 1078593A1 HK 06100346 A HK06100346 A HK 06100346A HK 1078593 A1 HK1078593 A1 HK 1078593A1
Authority
HK
Hong Kong
Prior art keywords
cancer
tumor
target
antibody against
specific antigen
Prior art date
Application number
HK06100346.5A
Other languages
English (en)
Inventor
Kimihisa Ichikawa
Shu Takahashi
Toshinori Agatsuma
Keisuke Fukuchi
Takehiro Hirai
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HK1078593A1 publication Critical patent/HK1078593A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK06100346.5A 2003-03-10 2006-01-09 Antibody against a tumor-specific antigen as target HK1078593A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003063648 2003-03-10
PCT/JP2004/003048 WO2004081050A1 (ja) 2003-03-10 2004-03-09 癌特異的抗原を標的とした抗体

Publications (1)

Publication Number Publication Date
HK1078593A1 true HK1078593A1 (en) 2006-03-17

Family

ID=32984436

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100346.5A HK1078593A1 (en) 2003-03-10 2006-01-09 Antibody against a tumor-specific antigen as target

Country Status (20)

Country Link
US (4) US7855056B2 (no)
EP (1) EP1602669B1 (no)
JP (1) JP4462964B2 (no)
KR (1) KR20050116374A (no)
CN (2) CN1784426A (no)
AT (1) ATE434044T1 (no)
AU (1) AU2004220182B2 (no)
BR (1) BRPI0408238A (no)
CA (1) CA2518787A1 (no)
DE (1) DE602004021567D1 (no)
DK (1) DK1602669T3 (no)
ES (1) ES2327408T3 (no)
HK (1) HK1078593A1 (no)
MX (1) MXPA05009715A (no)
NO (1) NO20054631L (no)
NZ (1) NZ542220A (no)
RU (1) RU2345090C2 (no)
TW (1) TW200508249A (no)
WO (1) WO2004081050A1 (no)
ZA (1) ZA200507298B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060030066A (ko) * 2003-07-02 2006-04-07 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US20110195440A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Systems and methods for identifying allergies
EP2613380B1 (en) 2010-11-05 2015-03-18 LG Chem, Ltd. Enhanced-stability rechargeable battery
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US20140224373A1 (en) * 2013-02-12 2014-08-14 MPS Enterprises, Inc. Lay-flat hose for oilfield hydraulic fracturing operations
PT3204417T (pt) * 2014-10-10 2020-10-08 Innate Pharma Bloqueio de cd73
KR102665199B1 (ko) * 2018-11-15 2024-05-14 삼성디스플레이 주식회사 레이저 장치 및 이를 이용한 기판 식각 방법
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5728821A (en) 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
CA2331998A1 (en) 1998-05-08 1999-11-18 Toyama Chemical Co., Ltd. Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same
NZ517372A (en) 1999-07-29 2004-04-30 Medarex Inc Human monoclonal antibodies to HER2/neu
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002016603A2 (en) * 2000-08-21 2002-02-28 Millennium Pharmaceuticals, Inc. 23228, a novel human tetraspanin family member and uses thereof
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
EP1434881A4 (en) * 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1571968A4 (en) 2002-04-16 2007-10-17 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
KR20060030066A (ko) 2003-07-02 2006-04-07 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
EP1602669B1 (en) 2009-06-17
NZ542220A (en) 2008-04-30
JP4462964B2 (ja) 2010-05-12
NO20054631L (no) 2005-12-09
TW200508249A (en) 2005-03-01
NO20054631D0 (no) 2005-10-07
CN102151334A (zh) 2011-08-17
US7361340B2 (en) 2008-04-22
US20070166312A1 (en) 2007-07-19
EP1602669A1 (en) 2005-12-07
US7741447B2 (en) 2010-06-22
US20080146785A1 (en) 2008-06-19
US20060127405A1 (en) 2006-06-15
US20070025996A1 (en) 2007-02-01
BRPI0408238A (pt) 2006-03-01
CN1784426A (zh) 2006-06-07
DE602004021567D1 (de) 2009-07-30
US7855056B2 (en) 2010-12-21
WO2004081050A1 (ja) 2004-09-23
CA2518787A1 (en) 2004-09-23
RU2005128277A (ru) 2006-06-10
RU2345090C2 (ru) 2009-01-27
JP2004290187A (ja) 2004-10-21
AU2004220182B2 (en) 2007-12-06
ZA200507298B (en) 2006-06-28
KR20050116374A (ko) 2005-12-12
MXPA05009715A (es) 2005-10-18
EP1602669A4 (en) 2006-08-09
ES2327408T3 (es) 2009-10-29
ATE434044T1 (de) 2009-07-15
DK1602669T3 (da) 2009-09-14
AU2004220182A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2003080582A3 (de) Fredericamycin-derivate
HK1078593A1 (en) Antibody against a tumor-specific antigen as target
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2005030121A3 (en) Compounds, compositions and methods
NO20055209D0 (no) Peptabody for cancerbehandling
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
HK1077193A1 (en) Alpha-7 nicotinic receptor agonists and statins incombination
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
ATE408601T1 (de) Fredericamycin-derivate
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
HK1115528A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
WO2006113579A3 (en) Tumor inhibition by modulating sprouty expression or activity
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2004015063A3 (en) Amplification and overexpression of oncogenes
SI1716128T1 (sl) Substituirane 4,5,6,7-tetrahidro-benzotiazol-2-ilaminske spojine
WO2006029406A3 (en) Methods for treating bone tumors using bone morphogenic proteins
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
GEP20125516B (en) Therapeutic uses of inhibitors of rtp801

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130309